Entera Bio director awarded 25,014 shares, options
Entera Bio Ltd. director Germano Geno J reported equity compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Entera Bio Ltd. director Germano Geno J reported equity compensation. He received 25,014 ordinary shares on August 7, 2026 in lieu of cash director fees for the first two quarters of 2026, raising his direct holdings to 65,014 shares. He was also granted stock options for 50,000 and 43,014 ordinary shares at an exercise price of 1.3700 per share, expiring May 7, 2036 and vesting over one- and three-year schedules starting February 4, 2026, with full acceleration upon a Change in Control under the company’s 2018 Equity Incentive Plan.
Insider Trade Summary
Grant/Award: 118,028 shares
Grant/Award
3 txns
Insider
Germano Geno J
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F2 | 50,000 | $0.00 | $0.00 |
| Grant/Award | Stock Option (right to buy) F3 | 43,014 | $0.00 | $0.00 |
| Grant/Award | Ordinary Shares, par value NIS 0.0000769 per share F1 | 25,014 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 93,014 contracts (Direct);
Ordinary Shares, par value NIS 0.0000769 per share — 65,014 shares (Direct)
Footnotes (3)
- F1. The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.
- F2. Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on February 4, 2026, with one-third of the options vesting on February 4, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")).
- F3. Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest on a quarterly basis over a one-year period that began on February 4, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan).
Key Figures
Ordinary share grant: 25,014 shares
Shares owned after grant: 65,014 shares
Option grant 1 size: 50,000 options
+5 more
8 metrics
Ordinary share grant
25,014 shares
Awarded to the director in lieu of cash fees for first and second quarter 2026 Board service.
Shares owned after grant
65,014 shares
Director’s direct ordinary share holdings following the August 7, 2026 equity award.
Option grant 1 size
50,000 options
Stock options to purchase ordinary shares approved May 7, 2026, subject to shareholder approval and Form S-8 filing.
Option grant 1 exercise price
1.3700 per share
Conversion or exercise price for the 50,000-share stock option grant.
Option grant 2 size
43,014 options
Additional stock options to purchase ordinary shares approved May 7, 2026.
Option grants expiration
May 7, 2036
Expiration date applicable to both option grants reported for the director.
Vesting start date
February 4, 2026
Both option grants begin vesting from this date under their respective schedules.
Shareholder approval date
July 14, 2026
Date on which shareholder approval for the option grants was obtained.
Key Terms
Registration Statement on Form S-8, Change in Control, 2018 Equity Incentive Plan, par value NIS 0.0000769
4 terms
Registration Statement on Form S-8 regulatory
"subject to the filing by the Company of a Registration Statement on Form S-8 registering"
A registration statement on Form S-8 is the U.S. Securities and Exchange Commission filing companies use to register shares they intend to grant to employees, directors, consultants or benefit plans under stock compensation programs. It matters to investors because it signals potential issuance of new shares tied to pay and incentives, which can increase the total shares outstanding — like adding more slices to a pie — reducing each existing share’s ownership and potentially affecting earnings per share and stock value.
Change in Control financial
"subject to full acceleration upon a Change in Control as defined in the Plan"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
2018 Equity Incentive Plan financial
"as defined in the Company's 2018 Equity Incentive Plan"
par value NIS 0.0000769 financial
"Ordinary Shares, par value NIS 0.0000769 per share"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Entera Bio (ENTX) director Germano Geno J receive?
He received 25,014 ordinary shares as a non-cash fee for first- and second-quarter 2026 director services, increasing his direct holdings to 65,014 shares. He also obtained stock options for 50,000 and 43,014 ordinary shares at an exercise price of 1.3700 per share.
What are the vesting terms for Germano Geno J’s Entera Bio (ENTX) stock options?
The 50,000-share option grant vests over a three year period beginning February 4, 2026, with one-third vesting on February 4, 2027 and the rest vesting quarterly thereafter. The 43,014-share grant vests quarterly over one year from February 4, 2026, both accelerating upon a Change in Control.
When were the Entera Bio (ENTX) option grants approved and what conditions applied?
Both option grants were approved by the Board on May 7, 2026, subject to shareholder approval and Form S-8 registration. Shareholders approved them on July 14, 2026, and the Registration Statement on Form S-8 for the underlying shares was filed on August 7, 2026.
What is the expiration date of the Entera Bio (ENTX) stock options reported?
Both stock option grants reported for director Germano Geno J expire on May 7, 2036. They cover 50,000 and 43,014 ordinary shares at an exercise price of 1.3700 per share and are subject to accelerated vesting upon a Change in Control under the company’s equity plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates